Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 3.02, 3.03, 8.01, 9.01 · 8-K

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Other Events

Item 1.01. Entry into a Material Definitive Agreement. Exchange Agreement On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor").…

Filed Nov 16, 2026Accepted Nov 16, 2026, 7:30 AM ESTCIK 1997296Accession 0001062993-26-006043
Share

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. 424B3 filingNov 16, 2026
  2. 424B5 filingNov 16, 2026
  3. 425 filingNov 9, 2026
  4. 425 filingNov 6, 2026
  5. 424B3 filingNov 6, 2026

Registered securities in this filing

Medicus Pharma Ltd. · 8-K · Filed 2026-11-16

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common shares, no par value

Symbol
MDCX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: CR20261113_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_CommonSharesNoParValueMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, exercisable for common shares

Symbol
MDCXW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: CR20261113_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_WarrantsExercisableForCommonSharesMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000106299326006043 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 3.02, 3.03, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement. Exchange Agreement On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor"). Pursuant to the Exchange Agreement, $10.5 million in principal amount of the Company's Secured Promissory Note A-1, issued on May 27, 2026 in the original principal amount of $12,864,225 (the "A-1 Note"), was partitioned from the A-1 Note into a new note (the "Partitioned Note"), and the Investor exchanged the Partitioned Note for 105,000 non-convertible, non-voting preferred shares of the Company (the "Preferred Shares"), in a form authorized under the Company's current Articles of Incorporation, as amended, at an issue price of $100 per Preferred Share (the "Exchange"). Upon the closing of the Exchange, the Partitioned Note was cancelled, the indebtedness exchanged under the A-1 Note was extinguished and the Company's obligations under the A-1 Note were reduced by the $10.5 million principal amount so exchanged. The unexchanged balance of the A-1 Note remains outstanding in accordance with its terms and continues to be secured by the security interests, guaranties and collateral agreements relating to the A-1 Note. The Company's Secured Promissory Note A-2, issued on September 1, 2026 (the "A-2 Note" and, together with the A-1 Note, the "A Notes"), was not affected by the Exchange. Following the Exchange, approximately $4.2 million of principal and accrued and unpaid interest remains outstanding under the A Notes, and the $8.2 million outstanding under the Company's Secured Promissory Note B, issued on May 27, 2026, was also not affected by the Exchange. The Company did not receive any cash proceeds from the Exchange. The Preferred Shares are not convertible into the Company's common shares, no par value (the "Common Shares"), and do not carry voting rights, except as required by the Business Corporations Act (Ontario). The Preferred Shares carry cumulative dividends at a rate of 8% per annum, payable in kind in additional Preferred Shares. The Preferred Shares are redeemable at the option of the Company, upon prior written notice, at a redemption price of $100 per Preferred Share plus all declared and unpaid dividends thereon to, but excluding, the redemption date, without premium or penalty. Upon a liquidation, dissolution or winding up of the Company, the Preferred Shares entitle the holders thereof to $100 per Preferred Share plus all declared and unpaid dividends thereon, in priority to the holders of the Common Shares. The Company expects to classify the Preferred Shares as permanent shareholders' equity. The foregoing description of the Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Registered Direct Offering On November 13, 2026, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the "Offering") (i) 97,973 Common Shares (the "Shares") at a price of $1.72 per Share and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,646,213 Common Shares (the "Pre-Funded Warrant Shares") at a price of $1.7199 per Pre-Funded Warrant, representing an aggregate of 1,744,186 Common Shares (including Pre-Funded Warrant Shares), for aggregate gross proceeds to the Company of approximately $3.0 million, before deducting estimated offering expenses payable by the Company and excluding any proceeds from the exercise of the Pre-Funded Warrants. The offering price per Share was the closing price of the Common Shares on The Nasdaq Capital Market ("Nasdaq") on November 12, 2026, and the offering price per Pre-Funded Warrant is equal to the offering price per Share less the $0.0001 exercise price of each Pre-Funded Warrant. The Offering closed on November 13, 2026. The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares were offered and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-292475) (the "Registration Statement"), including the base prospectus dated December 29, 2025 included therein, and a prospectus supplement dated November 13, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the "Securities Act"). The Company did not engage a placement agent or underwriter in connection with the Offering and did not pay any underwriting discounts, commissions or placement agent fees. The Pre-Funded Warrants were offered in lieu of Shares to any Purchaser whose purchase of Shares in the Offering would otherwise result in such Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Common Shares outstanding immediately following the Offering. Each Pre-Funded Warrant is exercisable for one Common Share at an exercise price of $0.0001 per share, is exercisable immediately upon issuance and does not expire, and may be exercised until it is exercised in full. A holder may exercise a Pre-Funded Warrant for cash or on a "cashless" basis, and cashless exercise is mandatory for so long as there is no effective registration statement or current prospectus available for the issuance of the Pre-Funded Warrant Shares or the amount of securities registered and available for issuance is insufficient. A holder may not exercise any portion of a Pre-Funded Warrant to the extent that, after giving effect to the exercise, the holder (together with its affiliates and any persons acting as a group with it) would beneficially own more than 4.99% (or, at the holder's election prior to issuance, 9.99%) of the Common Shares outstanding immediately after giving effect to the exercise; a holder may increase or decrease this limitation upon notice to the Company, provided that it may not exceed 9.99% and any increase will not be effective until the 61st day after notice is delivered. In addition, in order to comply with Nasdaq's shareholder approval requirements, the Company may not effect the exercise of any Pre-Funded Warrant, and no Purchaser will be entitled to exercise any portion of any Pre-Funded Warrant, that would cause (i) such Purchaser (together with its affiliates and any other persons acting as a group together with the Purchaser or any of the Purchaser's affiliates) to beneficially own more than 19.99% of the number of Common Shares outstanding immediately after giving effect to the exercise or (ii) a "change of control" of the Company within the meaning of Nasdaq Listing Rule 5635(b), in each case unless and until the Company has obtained shareholder approval in accordance with Nasdaq rules. This limitation may not be waived, increased or otherwise modified by the Company or any Purchaser, other than upon, and to the extent of, such shareholder approval, and applies to any successor to any Purchaser or transferee of a Pre-Funded Warrant. The exercise price and the number of Pre-Funded Warrant Shares are subject to adjustment for share dividends, splits, combinations and similar events, and the Pre-Funded Warrants provide for participation in certain pro rata rights offerings and distributions and for alternate consideration upon a fundamental transaction (each as described in the Pre-Funded Warrants). The Pre-Funded Warrants will not be listed on any securities exchange. The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers. The obligation of the Purchasers to consummate the purchase of securities in the Offering was contingent on the consummation of the Private Placements described below. The foregoing descriptions of the Purchase Agreement and the Pre-Funded Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement and the form of Pre-Funded Warrant, copies of which are filed as Exhibits 10.2 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. Private Placements Concurrently with the Offering, on November 13, 2026, the Company completed private placements of an aggregate of 726,730 Common Shares for cash to a limited number of accredited investors consisting primarily of members of the Company's management and directors, with such purchases led by a $750,000 investment by Dr. Raza Bokhari, the Company's Executive Chairman and Chief Executive Officer (purchasing through a controlled entity), at a purchase price of $1.72 per Common Share, being the closing price of the Common Shares on The Nasdaq Capital Market on November 12, 2026, for aggregate gross proceeds of approximately $1.25 million (the "Private Placements"). The Common Shares issued in the Private Placements were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder and are "restricted securities" within the meaning of Rule 144 under the Securities Act.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02. Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Private Placements is incorporated into this Item 3.02 by reference. The Preferred Shares were issued to the Investor in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, or, alternatively, by Section 4(a)(2) of the Securities Act, and the Common Shares issued in the Private Placements were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03. Material Modification to Rights of Security Holders. The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Preferred Shares is incorporated into this Item 3.03 by reference.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events. The information contained in Items 1.01, 3.02 and 3.03 of this Current Report on Form 8-K is incorporated into this Item 8.01 by reference. In connection with the Offering, the Company is filing as Exhibit 5.1 the opinion of Bennett Jones LLP regarding the validity of the issuance of the Shares and the Pre-Funded Warrant Shares and as Exhibit 5.2 the opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP regarding the validity of the Pre-Funded Warrants, together with the related consents as Exhibits 23.1 and 23.2, each for incorporation by reference into the Registration Statement. Additionally, since the quarter ended September 30, 2026 and as of November 12, 2026, the Company has completed sales of approximately 113,000 Common Shares under its at-the-market offering program for gross proceeds to the Company of approximately $0.35 million (the "ATM Sales" and, together with the Exchange, the Offering and the Private Placements, the "Transactions"). As previously disclosed in the Company's Current Report on Form 8-K filed with the SEC on May 27, 2026, on May 20, 2026, the Company received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its Market Value of Listed Securities ("MVLS") had been below $35 million for the previous 30 consecutive business days and that it was therefore not in compliance with Nasdaq Listing Rule 5550(b)(2). The Notice also stated that the Company did not then satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b)(1) or 5550(b)(3). The Company was provided a compliance period of 180 calendar days, or until November 16, 2026, to regain compliance with the MVLS requirement or satisfy an alternative listing standard, including the requirement to maintain stockholders' equity of at least $2.5 million under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard"). As a result of the completion of the Transactions, including the extinguishment of the indebtedness exchanged for the Preferred Shares, which the Company expects to classify as permanent shareholders' equity, and the issuance of Common Shares and Pre-Funded Warrants in the Offering and of Common Shares in the Private Placements and the ATM Sales, the Company has increased its shareholders' equity and believes that, as of November 13, 2026, after giving effect to the Transactions, its unaudited pro forma shareholders' equity was approximately $3.0 million. Accordingly, the Company believes that it has regained compliance with Nasdaq Listing Rule 5550(b) by satisfying the Equity Standard. The pro forma shareholders' equity amount reflects the Company's preliminary assessment of the accounting treatment of the Transactions, including classification of the Preferred Shares as permanent equity, the net proceeds of the Offering, the Private Placements and the ATM Sales and the Company's estimated results of operations from October 1, 2026 through November 13, 2026. Nasdaq has not yet confirmed that the Company has regained compliance with its financial continued listing requirements. The Company expects that Nasdaq will continue to monitor the Company's ongoing compliance with the Equity Standard and, if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting. There can be no assurance that Nasdaq will determine that the Company has regained compliance as a result of the Transactions, or that the Company will be able to maintain compliance with the Equity Standard or Nasdaq's other continued listing requirements in the future.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.